Zimmer Biomet announced Surgeon-Guided Autonomy, a new technology category designed to enhance orthopedic surgery by keeping surgeons in control while automating cognitive and physical tasks. This framework, introduced at the American Association of Hip and Knee Surgeons meeting, integrates surgical planning, execution, and recovery into a continuous loop called Predict, Perform, Recover. The goal is to reduce surgeon burden without replacing their expertise, using intelligent systems that learn from each case to improve outcomes. Zimmer Biomet aims to lead this shift in orthopedic surgery by connecting robotics, data, and surgeon intent across the entire care journey.
Zimmer Biomet's introduction of Surgeon-Guided Autonomy highlights its innovation in orthopedic surgery. On Pluang, Zimmer Biomet Holdings Inc (ZBH) trades at USD 106.85 with no change in price as of Nov 06, 2026 19:41 WIB. The stock has a market cap of $20.22 billion and a dividend yield of 0.9%, while current order activity shows 100% selling interest.
